FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours Worse Survival Observed Among Patients Diagnosed with Cancer During the First 2 Years of the COVID-19 Pandemic MOST POPULAR Ground-breaking trial pilots new tests to detect lung cancer earlier June 16, 2021 New on NCI’s Website for July 2023 – Researcher/Trainee Special Edition July 21, 2023 Thank you! March 22, 2021 Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas July 10, 2023 Load more HOT NEWS Risk of Anal Cancer Significantly Lower with Treatment for Anal High-Grade... Foodie Friday: Butternut Squash Macaroni Casserole EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma
